The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Move strengthens footprint in Western India and expands multi-specialty care network
The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Submission based on results from pivotal phase III trial showing all primary endpoints met
The product will be launched in March 2024
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Effective disaster response and management is a collaborative work
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
Subscribe To Our Newsletter & Stay Updated
